Resultado de búsqueda
13 de nov. de 2003 · We conducted the Valsartan in Acute Myocardial Infarction (VALIANT) trial to test the hypothesis that treatment with valsartan, an angiotensin-receptor blocker, alone or in combination with...
Background: The VALsartan In Acute myocardial iNfarcTion (VALIANT) trial compared outcomes with: (1) angiotensin-converting enzyme inhibition (ACEI) with the reference agent captopril; (2) angiotensin-receptor blockade (ARB) with valsartan; or (3) both in patients with heart failure (HF) and/or left ventricular systolic dysfunction (LVSD) after ...
23 de jun. de 2005 · VALIANT was a randomized, controlled trial of treatment with valsartan, captopril, or both in 14,703 patients with a first or subsequent acute myocardial infarction complicated by heart failure...
26 de sept. de 2018 · The wearable cardioverter–defibrillator may protect against sudden death during the immediate period after myocardial infarction, before ICD implantation is indicated under current guidelines...
1 de ene. de 2003 · The goal of the trial was to evaluate the effect of the angiotensin-receptor blocker (ARB) valsartan, the angiotensin-converting enzyme (ACE) inhibitor captopril, and the combination of the two on mortality in patients with myocardial infarction (MI) complicated by left ventricular (LV) systolic dysfunction, heart failure, or both.
13 de nov. de 2003 · In a double-blind trial, we compared the effect of the angiotensin-receptor blocker valsartan, the ACE inhibitor captopril, and the combination of the two on mortality in this population of patients.
Methods: Valsartan in Acute Myocardial Infarction (VALIANT) is a multicenter, double-blind, randomized, active controlled parallel group study comparing the efficacy and safety of long-term treatment with valsartan, captopril, and their combination in high-risk patients after MI.
